

Tanezumab improves scores for pain, function in osteoarthritis

3 July 2019



differences versus placebo: ± 0.60 and ± 0.73 , respectively). Decreases were seen in the WOMAC Physical Function scores of 7.2 to 3.7, 7.4 to 3.6, and 7.4 to 4.5, respectively (differences versus placebo: ± 0.66 and ± 0.89 , respectively). There were decreases in the mean patient global assessment of [osteoarthritis](#) scores from 3.4 to 2.4, 3.5 to 2.4, and 3.5 to 2.7, respectively (differences versus [placebo](#), ± 0.22 and ± 0.25 , respectively).

"Further research is needed to determine the clinical importance of these efficacy and adverse event findings," the authors write.

Several authors disclosed [financial ties](#) to [pharmaceutical companies](#), including Pfizer and Eli Lilly, which manufacture tanezumab and funded the study.

More information: [Abstract/Full Text \(subscription or payment may be required\)](#)
[Editorial \(subscription or payment may be required\)](#)

(HealthDay)—For patients with osteoarthritis (OA) of the knee or hip, tanezumab is associated with significant improvements in pain and physical function versus placebo, according to a study published in the July 2 issue of the *Journal of the American Medical Association*.

Thomas J. Schnitzer, M.D., Ph.D., from the Northwestern University Feinberg School of Medicine in Chicago, and colleagues randomly assigned patients with hip or knee OA with inadequate response to OA analgesics to subcutaneous administration of tanezumab 2.5 mg at day one and week eight, tanezumab 2.5 mg at day one and 5 mg at week eight, or placebo (231, 233, and 232 [patients](#), respectively).

The researchers observed decreases in the mean Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) Pain scores from 7.1 to 3.6 for tanezumab 2.5 mg, 7.3 to 3.6 for tanezumab 2.5/5 mg, and 7.3 to 4.4 for placebo from baseline to week 16 (least squares mean

Copyright © 2019 [HealthDay](#). All rights reserved.

APA citation: Tanezumab improves scores for pain, function in osteoarthritis (2019, July 3) retrieved 11 November 2022 from <https://medicalxpress.com/news/2019-07-tanezumab-scores-pain-function-osteoarthritis.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.